Trial Profile
Pilot Integrated Biomarker Study of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Resectable Metastatic Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pepinemab (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Pharmacodynamics
- 22 Feb 2024 Planned End Date changed from 31 Dec 2031 to 15 Dec 2032.
- 31 Oct 2023 According to a Vaccinex media release, data from this study will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- 31 Oct 2023 Interim results from this study presented in the Vaccinex Media Release